FDA approves Pfizer’s rheumatoid arthritis treatment
Nov 14, 2012
Federal regulators recently approved Pfizer’s new Xeljanz treatment for rheumatoid arthritis. Xeljanz was approved for patients with moderate to severe rheumatoid arthritis who did not benefit from...
Pfizer gets FDA approval for rheumatoid arthritis treatment
By
McKnight's Staff
Nov 09, 2012
Federal regulators approved Pfizer’s new Xeljanz treatment for rheumatoid arthritis Tuesday. The potentially lucrative drug is now poised to enter a market that already features Humira, Abbott Laboratories’...
Following Hurricane Sandy, drug makers get back to business
Nov 07, 2012
The typical long-term care resident requires eight or more medications daily. So with Hurricane Sandy ripping through the pharmaceutical corridor last week, many operators were rightfully concerned about...
Experimental Alzheimer’s drug fails to deliver in closely watched clinical trial
By
McKnight's Staff
Jul 25, 2012
Alzheimer’s researchers met with disappointment Monday when officials from Pfizer announced that the experimental drug bapineuzumab failed to improve dementia symptoms in a Phase 3 trial.
Higher dose of Alzheimer’s drug approved despite FDA warnings, report shows
By
McKnight's Staff
Mar 26, 2012
Makers of the Alzheimer’s drug Aricept released a higher dosage version of the medication despite concerns about side effects and reduced efficacy, a study reports.